OTCMKTS:RBGLY - Reckitt Benckiser Group Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 11
  • Breakdown:
  • 3 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$17.24
▼ -0.09 (-0.52%)
1 month | 3 months | 12 months
Get New Reckitt Benckiser Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RBGLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RBGLY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for Reckitt Benckiser Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $17.24.
Hold
The current consensus among 11 polled investment analysts is to hold stock in Reckitt Benckiser Group. This rating has held steady since October 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/12/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 2 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 2 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 3 sell ratings
11/3/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 3 sell ratings
12/3/2020

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 3 sell ratings

DateBrokerageActionRatingPrice TargetDetails
11/19/2020Jefferies Financial GroupDowngradeHold ➝ Underperform
i
11/11/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform
i
11/6/2020Royal Bank of CanadaUpgradeUnderperform ➝ Sector Perform
i
10/23/2020Berenberg BankReiterated RatingBuy
i
10/21/2020UBS GroupReiterated RatingBuy
i
10/21/2020Societe GeneraleReiterated RatingSell
i
10/12/2020Sanford C. BernsteinInitiated CoverageUnderperform
i
9/30/2020BarclaysReiterated RatingOverweight
i
9/3/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
i
7/30/2020Berenberg BankReiterated RatingBuy
i
7/29/2020JPMorgan Chase & Co.Reiterated RatingOverweight
i
7/29/2020UBS GroupReiterated RatingBuy
i
7/29/2020BarclaysReiterated RatingOverweight
i
7/29/2020Royal Bank of CanadaReiterated RatingUnderperform
i
7/29/2020Credit Suisse GroupReiterated RatingNeutral
i
7/10/2020Berenberg BankReiterated RatingBuy
i
6/29/2020UBS GroupUpgradeNeutral ➝ Buy
i
6/26/2020JPMorgan Chase & Co.Reiterated RatingOverweight
i
6/23/2020BarclaysReiterated RatingOverweight
i
6/15/2020Morgan StanleyReiterated RatingOverweight
i
5/4/2020JPMorgan Chase & Co.Reiterated RatingOverweight
i
4/7/2020Morgan StanleyReiterated RatingOverweight
i
3/18/2020Jefferies Financial GroupUpgradeUnderperform ➝ Hold
i
10/16/2019Berenberg BankInitiated CoverageBuy
i
7/5/2019BNP ParibasReiterated RatingOutperform ➝ Neutral
i
7/2/2019Societe GeneraleDowngradeBuy ➝ Sell
i
6/28/2019HSBCInitiated CoverageBuy ➝ Buy
i
1/24/2019Jefferies Financial GroupDowngradeHold ➝ Underperform
i
11/20/2018BNP ParibasUpgradeNeutral ➝ Outperform
i
5/4/2018Credit Suisse GroupReiterated RatingNeutral ➝ Underperform
i
4/3/2018Deutsche Bank AktiengesellschaftReiterated RatingBuy
i
3/23/2018Deutsche Bank AktiengesellschaftReiterated RatingBuy
i
3/22/2018Societe GeneraleUpgradeHold ➝ Buy
i
2/20/2018Credit Suisse GroupReiterated RatingOutperform ➝ Neutral
i
12/18/2017JPMorgan Chase & Co.Reiterated RatingBuy
i
9/7/2017JPMorgan Chase & Co.Reiterated RatingNeutral
i
9/5/2017BNP ParibasReiterated RatingOutperform ➝ Neutral
i
7/26/2017Kepler Capital MarketsDowngradeBuy ➝ Hold
i
7/6/2017Jefferies Financial GroupDowngradeBuy ➝ Hold
i
6/22/2017Societe GeneraleReiterated RatingBuy ➝ Hold
i
3/28/2017JPMorgan Chase & Co.Reiterated RatingNeutral
i
2/6/2017Royal Bank of CanadaDowngradeSector Perform ➝ Underperform
i
1/31/2017JPMorgan Chase & Co.Reiterated RatingNeutral
i
1/25/2017UBS GroupReiterated RatingNeutral
i
1/25/2017Berenberg BankUpgradeHold ➝ Buy
i
1/25/2017Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
i
12/8/2016Morgan StanleyInitiated CoverageEqual ➝ Equal Weight
i
9/22/2016JPMorgan Chase & Co.Reiterated RatingNeutral
i
9/7/2016BNP ParibasDowngradeOutperform ➝ Neutral
i
9/1/2016CitigroupInitiated CoverageBuy
i
8/25/2016Credit Suisse GroupLower Price TargetOutperform$6,500.00 ➝ $6,100.00
i
6/30/2016MacquarieInitiated CoverageOutperform
i
6/30/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
4/22/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy
i
4/15/2016JPMorgan Chase & Co.Reiterated RatingBuy
i
2/17/2016InvestecUpgradeSell ➝ Hold
i
2/15/2016S&P Equity ResearchReiterated RatingBuy
i
12/16/2015JPMorgan Chase & Co.Reiterated RatingBuy
i
(Data available from 12/3/2015 forward)
Reckitt Benckiser Group logo
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands. It also provides analgesics; footcare and footwear products; sore throat medications; and women's beauty products under the Nurofen, Scholl, Strepsils, and Veet brand. In addition, the company offers fragrances and devices; water softeners; home cleaning products; dish washes; toilet bowl cleaners; disinfectants; sprays, baits, and plug-ins for pest control; stain removals; and fabric washing products under the Air Wick, Calgon, Cillit Bang, Finish, Harpic, Lysol, Mortein, Vanish, and Woolite brands, as well as infant and child nutrition products under the Enfamil and Nutramigen brands. It operates in the United States, Canada, Europe, Russia/CIS, Turkey, Israel, Australia, New Zealand, and internationally. The company was founded in 1823 and is headquartered in Slough, the United Kingdom.
Read More

Today's Range

Now: $17.24
$17.15
$17.45

50 Day Range

MA: $18.26
$17.16
$19.33

52 Week Range

Now: $17.24
$12.76
$21.00

Volume

568,530 shs

Average Volume

582,905 shs

Market Capitalization

$61.30 billion

P/E Ratio

19.15

Dividend Yield

1.96%

Beta

0.69